Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

Aims: Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and efficacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years. Methods: Participants were randomized to receive once-daily liraglutide 1....

Descripción completa

Detalles Bibliográficos
Autores principales: Garber, A, Henry, R R, Ratner, R, Hale, P, Chang, C T, Bode, B
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084519/
https://www.ncbi.nlm.nih.gov/pubmed/21205128
http://dx.doi.org/10.1111/j.1463-1326.2010.01356.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084519/
https://www.ncbi.nlm.nih.gov/pubmed/21205128
http://dx.doi.org/10.1111/j.1463-1326.2010.01356.x

Ejemplares similares